

# FAMILIAL HYPERCHOLESTEROLAEMIA - Rare Forms of Familial Hypercholesterolaemia

Head :Boileau Catherine, U781

Last update : 08/04/2014 | Version : 1 | ID : 60131

## General

### Identification

Detailed name Rare Forms of Familial Hypercholesterolaemia

Sign or acronym FAMILIAL HYPERCHOLESTEROLAEMIA

CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation Accord CNIL : 28/03/2006

### General Aspects

Medical area Cardiology  
General practice

Health determinants Genetic

Others (details) Familial hypercholesterolaemia

Keywords lipid profile, cardiovascular complications, severity, Health episodes, response to treatment

### Scientific investigator(s) (Contact)

Name of the director Boileau  
Surname Catherine  
Address 75015 PARIS  
Email catherine.boileau@inserm.fr  
Unit U781  
Organization INSERM

### Collaborations

### Funding

Funding status	Public
Details	PHRC NATIONAL
<b>Governance of the database</b>	
Sponsor(s) or organisation(s) responsible	INSERM
Organisation status	Public
<b>Additional contact</b>	
<b>Main features</b>	
<b>Type of database</b>	
Type of database	Study databases
Study databases (details)	Cohort study
Database recruitment is carried out by an intermediary	A selection of health institutions and services
Database recruitment is carried out as part of an interventional study	No
Additional information regarding sample selection.	Inclusion method: prospective. Details concerning this number: 1,000 applicants 250 multiplex families (at least 15 subjects per family)
<b>Database objective</b>	
Main objective	General objective: To assess and compare the morbidity and mortality of each form of familial hypercholesterolaemia. Secondary objective: To develop the most effective intervention methods possible and establish better targeted treatment tools.
Inclusion criteria	Autosomal dominant hypercholesterolaemia
<b>Population type</b>	
Age	Adulthood (19 to 24 years) Adulthood (25 to 44 years) Adulthood (45 to 64 years)
Population covered	Sick population
Gender	Male

Woman

Geography area National

Detail of the geography area France

## Data collection

### Dates

Date of first collection (YYYY or MM/YYYY) 03/1992

### Size of the database

Size of the database (number of individuals) [500-1000[ individuals

Details of the number of individuals 1000

### Data

Database activity Data collection completed

Type of data collected Clinical data  
Declarative data  
Biological data

Clinical data (detail) Direct physical measures  
Medical registration

Declarative data (detail) Face to face interview

Biological data (detail) Type of samples taken: blood, lipid profile, DNA and establishment of lymphoblastoid cell lines

Presence of a biobank Yes

Contents of biobank Cell lines  
DNA

Details of biobank content DNA bank, lymphoblastoid lines

Health parameters studied Health event/morbidity  
Health event/mortality

### Procedures

Data collection method Interview: paper questionnaire (manual input) Clinical examinations: handwritten (manual input) Biological analysis: handwritten (manual input)

Participant monitoring	Yes
Details on monitoring of participants	(Indefinite duration)

Links to administrative sources	No
---------------------------------	----

## Promotion and access

### Promotion

Link to the document	<a href="http://www.ncbi.nlm.nih.gov/pubmed/25052769">http://www.ncbi.nlm.nih.gov/pubmed/25052769</a>
----------------------	---

### Access

Terms of data access (charter for data provision, format of data, availability delay)	Data may not be used by academic teams Data may not be used by industrial teams
---	---

Access to aggregated data	Access on specific project only
---------------------------	---------------------------------

Access to individual data	No access
---------------------------	-----------